Short CDAI: Development and validation of a shortened and simplified Crohnʼs disease activity index

Thia, Kelvin T.; Faubion, William A.; Loftus, Edward V.; Persson, Tore; Persson, Anders; Sandborn, William J.

doi:10.1002/ibd.21400

Cited by 114 publications

(72 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CDAI has evolved as the gold standard for clinical trials 4. Although the CDAI may be adequate for measuring disease activity in some circumstances, it has some important limitations including the fact that approximately 40% of the index is derived from three subjective criteria (diarrhoea, abdominal pain and sense of well-being) which account for 80% of the responsiveness to change,2 while it does not take into account the more objective measures of inflammation (such as C-reactive protein (CRP) and endoscopic lesions) in a disease which is by definition inflammatory in nature.…”

Section: Introductionmentioning

confidence: 99%

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

Peyrin–Biroulet

Reinisch

Colombel

et al. 2013

Gut

422

225

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

Peyrin–Biroulet

Reinisch

Colombel

et al. 2013

Gut

422

225

View full text Add to dashboard Cite

show abstract

“…11,12 Knowing patients' CD activity is of great importance in clinical practice as well as medical research. Two studies have thus far developed a shortened assessment of CD activity derived from the CDAI 13,14 with the aim of easing the use of the CDAI in research. However, these short indices still require that patients record and sum up their disease activity for 7 consecutive days using a disease activity diary.…”

mentioning

confidence: 99%

Development of the Patient Harvey Bradshaw Index and a Comparison With a Clinician-based Harvey Bradshaw Index Assessment of Crohn’s Disease Activity

Evertsz¹,

Hoeks²,

Nieuwkerk³

et al. 2013

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Goals and Background:The objective is to develop a patient-based Harvey Bradshaw Index (P-HBI) of Crohn's Disease (CD) activity and to compare it with the clinician-based HBI of CD activity in CD outpatients.Study: Consecutive patients with CD randomly completed the P-HBI either before or after the consultation. The gastroenterologist assessed patient's CD activity on the same day. Overall agreement between HBI and P-HBI was calculated with Spearman's r and Mann-Whitney U test. Agreement regarding active disease versus remission and agreement at item level was calculated by percent agreement and Cohen's k.Results: One hundred eighty-one (response rate 88.3%) CD patients participated. P-HBI and HBI showed a large correlation (r s = 0.82). The medians (interquartile range) of the total HBI (2; 0 to 4) and P-HBI (4; 1 to 7) were statistically significantly different (z = À 8.411; P < 0.001). Fortunately, in 82.6% of the cases this difference between clinicians and patients was not clinically significant (< 3.2). The percentage agreement between clinician and patient, judging CD as active or as in remission, was 77%, r s = 0.56, k = 0.52, indicating a moderate agreement. P-HBI and HBI on frequent extraintestinal manifestations in CD varied from less than chance (k = À 0.02) to a perfect agreement (k = 1). Patients tended to report more symptoms while completing the patientbased questionnaire compared to what they reported to the clinician during consultation. Conclusions:The P-HBI is the first step in developing a potential promising tool given its adequate agreement with the original HBI and its feasibility, especially in patients with low scores. Future research is necessary to develop a validated patient-based version studied in several patient populations.

show abstract

“…The Crohn's disease activity index (CDAI) has evolved as the gold standard for clinical trials [12], but analysis of data from a large, prospective, well-defined subpopulation of the SONIC trial [13] showed that CDAI was not accurate to predict C-reactive protein (CRP) normalization and/or mucosal healing in CD as half the patients with CD in clinical remission had endoscopic and/or CRP evidence of residual active CD [14]. Objective outcome measures of CD activity, in addition to assessment of clinical symptoms, are obviously needed to evaluate disease activity in CD.…”

Section: Monitoring Disease Activity In Crohn's Diseasementioning

confidence: 99%

Maintenance therapy for Crohn’s disease

Önal

Beyazıt

Altınbaş

et al. 2015

European Journal of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Crohn's disease (CD) is a chronic, persistent, and destructive disorder with different forms of clinical behavior and the disease appears to be progressive over the long term. Providing greater levels of mucosal healing and resolution of clinical symptoms may modify the course of CD. This will often necessitate long-term therapy with immunosuppressant or biological therapies. Both these classes of drugs have side-effects and the latter are also very expensive. Identification of a subgroup of patients with a low risk of relapse and validation of the relevant predictors in various cohort studies are the key points to be able to cease immunosuppressant and/or biological therapy in patients with CD in stable remission. The individual parameters 'mucosal healing', 'deep remission', 'fecal calprotectin', and 'C-reactive protein' or various combinations of these parameters seem to be promising tools for predicting successful withdrawal of maintenance therapy.

show abstract

Short CDAI: Development and validation of a shortened and simplified Crohnʼs disease activity index

Abstract: The short CDAI is a valid, reliable, and responsive tool for the measurement of CD activity.

Cited by 114 publications

References 20 publications

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

Development of the Patient Harvey Bradshaw Index and a Comparison With a Clinician-based Harvey Bradshaw Index Assessment of Crohn’s Disease Activity

Maintenance therapy for Crohn’s disease

Contact Info

Product

Resources

About